Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study

Main Article Content

Michael Cork
Sheffield Dermatology Research, University of Sheffield, Sheffield, UK

Diamant Tha?i
University of L?beck, Lubeck, Germany

Lawrence Eichenfield
University of California, San Diego, CA; Rady Children?s Hospital, San Diego, CA

Peter Arkwright
University of Manchester, Manchester, UK

Zhen Chen
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Mohamed Kamal
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

John O'Malley
Sanofi, Cambridge, MA

Ashish Bansal
Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Keywords

Atopic Dermatitis, Biologic, Dupilumab, Pediatrics, Safety, Efficacy

Abstract

Abstract not available.

References

1. Wollenberg A, et al. J Eur Acad Dermatol Venereol 2016;30:729-47.

2. Sidbury R, et al. J Am Acad Dermatol 2014;71:327-49.

3. Ring J, et al. J Eur Acad Dermatol Venereol. 2012;26:1176-93.

4. Drucker AM, et al. Br J Dermatol. 2018; 178:768-75.

5. Totri CR, et al. J Am Acad Dermatol. 2017; 76:281-5.

6. Macdonald LE, et al. Proc Natl Acad Sci U S A. 2014;111:5147-52.

7. Murphy AJ, et al. Proc Natl Acad Sci U S A. 2014;111:5153-8.

8. Cork MJ, et al. Br J Dermatol. 2020;182:85-96.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.104

Article Details

How to Cite
[1]
Cork, M., Tha?i, D., Eichenfield, L., Arkwright, P., Chen, Z., Kamal, M., O’Malley, J. and Bansal, A. 2020. Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to &lt; 12 Years with Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s104. DOI:https://doi.org/10.25251/skin.4.supp.104.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>